Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.43 |
| ▸ | CTSS | P25774 | 6/20 | 0.40 |
| ▸ | CTSK | P43235 | 5/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | GRN | P28799 | 1/20 | 0.34 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.34 |
| ▸ | HTRA1 | Q92743 | 6/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
| ▸ | CPA1 | P15085 | 1/20 | 0.30 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5635654 | 1.00 | CTSL (0.43) | CTSLCTSSCTSKCTSBGRN | |
| SCHEMBL5634729 | 0.84 | CTSS (0.38) | CTSSCTSKGRNSORT1 | |
| SCHEMBL15795581 | 0.83 | CTSK (0.44) | CTSLCTSSCTSKMME | |
| SCHEMBL5074738 | 0.83 | CTSS (0.42) | CTSLCTSSCTSKKDM4EGAA | |
| SCHEMBL14142063 | 0.83 | CTSS (0.42) | CTSLCTSSCTSKKDM4EGAA | |
| SCHEMBL15820386 | 0.81 | CTSS (0.40) | CTSSCTSK | |
| SCHEMBL14141779 | 0.80 | CA12 (0.42) | CTSLCTSSCTSKCTSBKDM4E | |
| SCHEMBL15819962 | 0.80 | CA12 (0.42) | CTSLCTSSCTSKCTSBKDM4E | |
| SCHEMBL15826162 | 0.79 | CTSS (0.39) | CTSSCTSK | |
| SCHEMBL1866494 | 0.77 | CNR2 (0.41) | CTSLCTSSCTSKCTSBGRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580802-B2 | Pyrrolo[2,3-D]pyrimidines as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-12 | — | — | US | disclosed |
| US-20070207995-A1 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207995-A1 | Deazapurines useful as inhibitors of Janus kinases | JAK1, JAK3, JAK2 | CTSL 4411/4885CTSS 4247/4885CTSK 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.